Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery (LUNG ART)
Primary Purpose
Non-small Cell Lung Cancer
Status
Unknown status
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
clinical observation
adjuvant therapy
3-dimensional conformal radiation therapy
Sponsored by
About this trial
This is an interventional treatment trial for Non-small Cell Lung Cancer focused on measuring stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer
Eligibility Criteria
INCLUSION CRITERIA :
- Histological evidence of non-small cell lung cancer (NSCLC)
- Complete resection by lobectomy, bilobectomy or pneumonectomy (i.e patients with positive margins) or extra-capsular mediastinal nodal extension breaching the surface of the pathological specimen should not to be included
- Mediastinal lymph node exploration (lymph node sampling or systematic dissection of lymph nodes at stations 2, 4 and 7 in case of upper/middle right-sided lung cancer; 4, 7, 8 and 9 in case of lower right-sided lung cancer; 5, 6 and 7 in case of upper left -sided lung cancer; 7, 8 and 9 in case of lower left-sided lung cancer is recommended)
- Pathologically or cytologically documented N2 mediastinal nodal involvement, at the time of surgery if no preoperative chemotherapy or before preoperative chemotherapy, according to the criteria of the joint AJCC and UICC classification, clinical N2 patients without cytological or histological documentation of mediastinal node involvement before preoperative chemotherapy can be included in the study if and only if, they have histologically confirmed N2 disease at the time of surgery
- Prior chemotherapy is allowed (pre-operative or post-operative adjuvant chemotherapy, or both)
- Patient aged ≥ 18 years
- Good Performance status (WHO ≤ 2)
- Fit enough to receive curative radiotherapy
- Adequate pulmonary function with post-operative FEV1 after surgery > 1 l or over 35% theoretical value
- Signed informed consent form
EXCLUSION CRITERIA:
- Documented metastases, (except for ipsilateral nodule(s) in a different lobe after pneumonectomy or bi-lobectomy)
- Major pleural or pericardial effusion
- Synchronous contra-lateral lung cancer
- Clinical progression during post-operative chemotherapy
- Previous chest radiotherapy
- Intention of concomitant chemotherapy during radiotherapy
- Weight loss in the previous 6 months before surgery ≥ 10 %
- Evidence of severe or uncontrolled systemic disease as judged by the investigator
- Recent (< 6 months) severe cardiac disease (arrhythmia, congestive heart failure, infarction, pace-maker) or pulmonary disease
Current or past history of neoplasm other than non-small cell lung cancer diagnosed within the last 5 years, except :
- basal cell carcinoma of the skin
- in situ carcinoma of the cervix A patient diagnosed for another neoplasm 5 years ago or more, treated and considered as cured may be included in the study if all the other criteria are respected.
- Pregnancy or breast feeding or inadequate contraceptive measures during treatment
- Patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and/or are incapable of undergoing regular controls
- Patient deprived of freedom or under guardianship
Sites / Locations
- Institut Gustave Roussy
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Radiotherapy
No radiotherapy
Arm Description
Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
Outcomes
Primary Outcome Measures
Disease-free survival (DFS)
Secondary Outcome Measures
Acute and late toxicity (with identification of predictive factors of toxicity)
Local control
Patterns of failure
Overall survival (OS)
Second cancers
Prognostic and predictive factors of treatment effect on DFS and OS
Cost per recurrence-free year of life
Full Information
NCT ID
NCT00410683
First Posted
December 11, 2006
Last Updated
November 18, 2020
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Collaborators
Intergroupe Francophone de Cancerologie Thoracique, The Christie NHS Foundation Trust, European Organisation for Research and Treatment of Cancer - EORTC
1. Study Identification
Unique Protocol Identification Number
NCT00410683
Brief Title
Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery
Acronym
LUNG ART
Official Title
Phase III Study Comparing Post-Operative Conformal Radiotherapy to No Post-Operative Radiotherapy in Patients With Completely Resected Non-Small Cell Lung Cancer and Mediastinal N2 Involvement [Lung ART]
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
February 2007 (Actual)
Primary Completion Date
July 2018 (Actual)
Study Completion Date
February 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Collaborators
Intergroupe Francophone de Cancerologie Thoracique, The Christie NHS Foundation Trust, European Organisation for Research and Treatment of Cancer - EORTC
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving radiation therapy after surgery is more effective than no radiation therapy in treating patients with non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared to no radiation therapy in treating patients with non-small cell lung cancer that has been completely removed by surgery.
Detailed Description
OBJECTIVES:
Primary
Compare the disease-free survival of patients with completely resected non-small cell lung cancer treated with conformal thoracic radiotherapy vs no radiotherapy.
Secondary
Determine the toxicity, in particular cardiac and pulmonary toxicity, of these regimens in these patients.
Compare the local control in patients treated with these regimens.
Determine patterns of recurrence in patients treated with these regimens.
Determine the overall survival of patients treated with these regimens.
Assess second cancers in patients treated with these regimens.
Assess prognostic factors and predictive factors of treatment effect on disease-free survival and overall survival of patients treated with these regimens.
Determine the cost per recurrence-free year of life.
OUTLINE: This is a multicenter, randomized study.
Patients are stratified according to participating center, prior chemotherapy (neoadjuvant alone vs adjuvant vs none), number of lymph stations involved (0 vs 1 vs ≥ 2), histology (squamous cell vs other), and use of pretreatment positron emission tomography scans (yes vs no). Patients are randomized to 1 of 2 treatment arms.
Arm I: Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
Arm II: Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to10 years.
PROJECTED ACCRUAL: A total of 700 patients will be accrued for this study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer
Keywords
stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Radiotherapy
Arm Type
Experimental
Arm Description
Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
Arm Title
No radiotherapy
Arm Type
Active Comparator
Arm Description
Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
Intervention Type
Other
Intervention Name(s)
clinical observation
Intervention Type
Procedure
Intervention Name(s)
adjuvant therapy
Intervention Type
Radiation
Intervention Name(s)
3-dimensional conformal radiation therapy
Primary Outcome Measure Information:
Title
Disease-free survival (DFS)
Time Frame
assessed up every 3 and 6 months after randomization, every 6 months for the fist three years and yearly afterward
Secondary Outcome Measure Information:
Title
Acute and late toxicity (with identification of predictive factors of toxicity)
Time Frame
assessed up at 3 and 6 months after randomization and then yearly afterward; And in case of event
Title
Local control
Time Frame
assessed up at 3 and 6 months after randomization and then yearly afterward; And in case of event
Title
Patterns of failure
Time Frame
assessed up at 3 and 6 months after randomization and then yearly afterward; And in case of event
Title
Overall survival (OS)
Time Frame
assessed up In case of death whatever the cause
Title
Second cancers
Time Frame
Assessed up in case of event
Title
Prognostic and predictive factors of treatment effect on DFS and OS
Time Frame
assessed up at the end of the study
Title
Cost per recurrence-free year of life
Time Frame
Assessed up at the end of the study
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA :
Histological evidence of non-small cell lung cancer (NSCLC)
Complete resection by lobectomy, bilobectomy or pneumonectomy (i.e patients with positive margins) or extra-capsular mediastinal nodal extension breaching the surface of the pathological specimen should not to be included
Mediastinal lymph node exploration (lymph node sampling or systematic dissection of lymph nodes at stations 2, 4 and 7 in case of upper/middle right-sided lung cancer; 4, 7, 8 and 9 in case of lower right-sided lung cancer; 5, 6 and 7 in case of upper left -sided lung cancer; 7, 8 and 9 in case of lower left-sided lung cancer is recommended)
Pathologically or cytologically documented N2 mediastinal nodal involvement, at the time of surgery if no preoperative chemotherapy or before preoperative chemotherapy, according to the criteria of the joint AJCC and UICC classification, clinical N2 patients without cytological or histological documentation of mediastinal node involvement before preoperative chemotherapy can be included in the study if and only if, they have histologically confirmed N2 disease at the time of surgery
Prior chemotherapy is allowed (pre-operative or post-operative adjuvant chemotherapy, or both)
Patient aged ≥ 18 years
Good Performance status (WHO ≤ 2)
Fit enough to receive curative radiotherapy
Adequate pulmonary function with post-operative FEV1 after surgery > 1 l or over 35% theoretical value
Signed informed consent form
EXCLUSION CRITERIA:
Documented metastases, (except for ipsilateral nodule(s) in a different lobe after pneumonectomy or bi-lobectomy)
Major pleural or pericardial effusion
Synchronous contra-lateral lung cancer
Clinical progression during post-operative chemotherapy
Previous chest radiotherapy
Intention of concomitant chemotherapy during radiotherapy
Weight loss in the previous 6 months before surgery ≥ 10 %
Evidence of severe or uncontrolled systemic disease as judged by the investigator
Recent (< 6 months) severe cardiac disease (arrhythmia, congestive heart failure, infarction, pace-maker) or pulmonary disease
Current or past history of neoplasm other than non-small cell lung cancer diagnosed within the last 5 years, except :
basal cell carcinoma of the skin
in situ carcinoma of the cervix A patient diagnosed for another neoplasm 5 years ago or more, treated and considered as cured may be included in the study if all the other criteria are respected.
Pregnancy or breast feeding or inadequate contraceptive measures during treatment
Patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and/or are incapable of undergoing regular controls
Patient deprived of freedom or under guardianship
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cecile Le Pechoux, MD
Organizational Affiliation
Gustave Roussy, Cancer Campus, Grand Paris
Official's Role
Study Chair
Facility Information:
Facility Name
Institut Gustave Roussy
City
Villejuif
State/Province
Val De Marne
ZIP/Postal Code
94805
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
34919827
Citation
Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, Nestle U, Boisselier P, Dansin E, Paumier A, Peignaux K, Thillays F, Zalcman G, Madelaine J, Pichon E, Larrouy A, Lavole A, Argo-Leignel D, Derollez M, Faivre-Finn C, Hatton MQ, Riesterer O, Bouvier-Morel E, Dunant A, Edwards JG, Thomas PA, Mercier O, Bardet A. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Jan;23(1):104-114. doi: 10.1016/S1470-2045(21)00606-9. Epub 2021 Dec 15. Erratum In: Lancet Oncol. 2022 Jul;23(7):e319.
Results Reference
derived
Learn more about this trial
Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery
We'll reach out to this number within 24 hrs